Global Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI09244963

Publication Date:

September 10, 2024

Pages:

115

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Chemotherapy-Induced Nausea and Vomiting (CINV) market size was valued at US$ 2511.8 million in 2023. With growing demand in downstream market, the Chemotherapy-Induced Nausea and Vomiting (CINV) is forecast to a readjusted size of US$ 3004.8 million by 2030 with a CAGR of 2.6% during review period.
The research report highlights the growth potential of the global Chemotherapy-Induced Nausea and Vomiting (CINV) market. Chemotherapy-Induced Nausea and Vomiting (CINV) are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Chemotherapy-Induced Nausea and Vomiting (CINV). 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Chemotherapy-Induced Nausea and Vomiting (CINV) market.
Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
Key Features:
The report on Chemotherapy-Induced Nausea and Vomiting (CINV) market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the Chemotherapy-Induced Nausea and Vomiting (CINV) market. It may include historical data, market segmentation by Type (e.g., CINV, PONV), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Chemotherapy-Induced Nausea and Vomiting (CINV) market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Chemotherapy-Induced Nausea and Vomiting (CINV) market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Chemotherapy-Induced Nausea and Vomiting (CINV) industry. This include advancements in Chemotherapy-Induced Nausea and Vomiting (CINV) technology, Chemotherapy-Induced Nausea and Vomiting (CINV) new entrants, Chemotherapy-Induced Nausea and Vomiting (CINV) new investment, and other innovations that are shaping the future of Chemotherapy-Induced Nausea and Vomiting (CINV).
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Chemotherapy-Induced Nausea and Vomiting (CINV) market. It includes factors influencing customer ' purchasing decisions, preferences for Chemotherapy-Induced Nausea and Vomiting (CINV) product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Chemotherapy-Induced Nausea and Vomiting (CINV) market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Chemotherapy-Induced Nausea and Vomiting (CINV) market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Chemotherapy-Induced Nausea and Vomiting (CINV) market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Chemotherapy-Induced Nausea and Vomiting (CINV) industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Chemotherapy-Induced Nausea and Vomiting (CINV) market.
麻豆原创 Segmentation:
Chemotherapy-Induced Nausea and Vomiting (CINV) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
CINV
PONV
Segmentation by application
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size 2019-2030
2.1.2 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Segment by Type
2.2.1 CINV
2.2.2 PONV
2.3 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Type
2.3.1 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Chemotherapy-Induced Nausea and Vomiting (CINV) Segment by Application
2.4.1 Hospitals
2.4.2 Ambulatory Surgical Centers
2.4.3 Diagnostic Centers
2.5 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Application
2.5.1 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Player
3.1 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Players (2019-2024)
3.1.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Chemotherapy-Induced Nausea and Vomiting (CINV) by Regions
4.1 Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size Growth (2019-2024)
4.3 APAC Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size Growth (2019-2024)
4.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Country (2019-2024)
5.2 Americas Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Type (2019-2024)
5.3 Americas Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Region (2019-2024)
6.2 APAC Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Type (2019-2024)
6.3 APAC Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) by Country (2019-2024)
7.2 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Type (2019-2024)
7.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) by Region (2019-2024)
8.2 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Regions (2025-2030)
10.1.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Regions (2025-2030)
10.1.2 Americas Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast
10.1.3 APAC Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast
10.1.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast
10.1.5 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast
10.2 Americas Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Country (2025-2030)
10.2.1 United States Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.2.2 Canada Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.2.3 Mexico Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.2.4 Brazil Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.3 APAC Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Region (2025-2030)
10.3.1 China Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.3.2 Japan Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.3.3 Korea Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.3.4 Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.3.5 India Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.3.6 Australia Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Country (2025-2030)
10.4.1 Germany Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.4.2 France Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.4.3 UK Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.4.4 Italy Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.4.5 Russia Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.5 Middle East & Africa Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Region (2025-2030)
10.5.1 Egypt Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.5.2 South Africa Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.5.3 Israel Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.5.4 Turkey Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.5.5 GCC Countries Chemotherapy-Induced Nausea and Vomiting (CINV) 麻豆原创 Forecast
10.6 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Type (2025-2030)
10.7 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.1.3 Merck Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Merck Main Business Overview
11.1.5 Merck Latest Developments
11.2 Eisai
11.2.1 Eisai Company Information
11.2.2 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.2.3 Eisai Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Eisai Main Business Overview
11.2.5 Eisai Latest Developments
11.3 ProStrakan
11.3.1 ProStrakan Company Information
11.3.2 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.3.3 ProStrakan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 ProStrakan Main Business Overview
11.3.5 ProStrakan Latest Developments
11.4 Helsinn Holding
11.4.1 Helsinn Holding Company Information
11.4.2 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.4.3 Helsinn Holding Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Helsinn Holding Main Business Overview
11.4.5 Helsinn Holding Latest Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Information
11.5.2 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.5.3 Mundipharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Mundipharma Main Business Overview
11.5.5 Mundipharma Latest Developments
11.6 Qilu Pharma
11.6.1 Qilu Pharma Company Information
11.6.2 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.6.3 Qilu Pharma Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Qilu Pharma Main Business Overview
11.6.5 Qilu Pharma Latest Developments
11.7 Teva
11.7.1 Teva Company Information
11.7.2 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.7.3 Teva Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Teva Main Business Overview
11.7.5 Teva Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.8.3 Novartis Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 Heron Therapeutics
11.9.1 Heron Therapeutics Company Information
11.9.2 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.9.3 Heron Therapeutics Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Heron Therapeutics Main Business Overview
11.9.5 Heron Therapeutics Latest Developments
11.10 Roche
11.10.1 Roche Company Information
11.10.2 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.10.3 Roche Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Roche Main Business Overview
11.10.5 Roche Latest Developments
11.11 Mylan
11.11.1 Mylan Company Information
11.11.2 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.11.3 Mylan Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Mylan Main Business Overview
11.11.5 Mylan Latest Developments
11.12 Tesaro
11.12.1 Tesaro Company Information
11.12.2 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Product Offered
11.12.3 Tesaro Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Tesaro Main Business Overview
11.12.5 Tesaro Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.